Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 24, 2013, Pages 7624-7627

  Song, Ya Li ^a,b   Dong, Yun Fang ^a,b   Yang, Tao ^a,b   Zhang, Chao Chao ^a,b   Su, Li Min ^a,b   Huang, Xin ^a,b   Zhang, Dong Nuan ^c   Yang, Geng Liang ^a,b   Liu, Yu Xin ^a,b  

^a HEBEI UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c AGRICULTURAL UNIVERSITY OF HEBEI   (China)

Author keywords

Anticancer; Bisindolylalkane; Indole; Thiochroman 4 one; Topoisomerase II

Indexed keywords

3,3' (6 CHLOROTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); 3,3' (6 FLUOROTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); 3,3' (6 METHOXYLTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); 3,3' (6 METHYLTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); 3,3' (7 FLUORO 6 METHYLTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); 3,3' (8 CHLOROTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); 3,3' (8 FLUOROTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); 3,3' (8 METHYLTHIOCHROMAN 4,4 DIYL)BIS(1H INDOLE); ANTINEOPLASTIC AGENT; BISINDOLYLALKANE; DNA TOPOISOMERASE (ATP HYDROLYSING); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL PROLIFERATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTICANCER; BISINDOLYLALKANE; INDOLE; THIOCHROMAN-4-ONE; TOPOISOMERASE II;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS;

EID: 84888436755     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.10.034     Document Type: Article

References (15)

1. D. Kumar, N. Kumar, S. Kumar, T. Singh, and C.P. Singh Int. J. Eng. Sci. Technol. 2 2010 2553
2. D. Kumar, M.K. Narayanam, K.H. Chang, and K. Shah Chem. Biol. Drug Des. 77 2011 182
3. N.R. Penthala, T.R. Yerramreddy, and P.A. Crooks Bioorg. Med. Chem. Lett. 21 2011 1411
4. S. Tsujii, K.L. Rinehart, S.P. Gunasekera, S. Cross, M.S. Lui, S.A. Pomponi, and M.C. Diaz J. Org. Chem. 53 1988 5446
5. G. Bifulco, I. Bruno, L. Minale, R. Riccio, A. Calignano, and C. Debitus J. Nat. Prod. 57 1994 1294
6. S. Morteza, A.Z. Mohammad, G.K. Hendrik, and T. Zahra Chem. Rev. 110 2010 2250
7. Y. Gong, G.L. Firestone, and L.F. Bjeldanes Mol. Pharmacol. 69 2006 1320
8. Stephen, H. S. US Patent 20,020,115,708, 2002.
9. J.C. Han, Y.P. So, J.K. Eun, J.M. Eun, K. Jin-kyung, and H.Y.P. Jung Mol. Carcinogen. 50 2011 100
10. M. Dorota, R. Magdalena, W. Irena, A. Elzbieta, and G. Beata Eur. J. Med. Chem. 44 2009 4136
11. W. Chao, D. Yean, K. Amin, C. Green, and L. Jong J. Med. Chem. 50 2007 3412
12. L. Xiao, and H. Li Chin. J. Org. Chem. 26 2006 979
13. Z.Y. Ma, G.L. Yang, G.Y. Yan, S.G. Zhu, and L. Guan Chin. J. Med. Chem. 18 2008 170
14. S.G. Zhu, G.L. Yang, Z.Y. Ma, C.L. Wei, and L.D. Guo Chin. J. New Drugs 17 2008 1034
15. S.Y. Cui, Y.X. Liu, G.L. Yang, B.L. Fang, and W. Tian Chin. Pharmacist. 13 2010 612